Malignant tumor of colon
|
|
0.050 |
GeneticVariation
|
BEFREE |
The GR/RR IRS1 genotypes were associated with an increased risk of colon cancers with the KRAS2 G12D mutation (OR 2.3, 95% CI 1.5, 3.5 versus controls, OR 1.7, 95% CI 1.1, 2.6 versus KRAS2 wild type), the "no 192" IGFI genotype increased the risk of the KRAS2 G13D mutation (OR 2.3, 95% CI 1.2, 4.2 versus controls, OR 2.1, 95% CI 1.1, 4.0 versus wild type), and the DD IRS2 genotype increased the risk of the G12V KRAS2 mutation (OR 1.8, 95% CI 0.9, 3.5 versus controls, OR 2.0, 95% CI 1.0, 4.0 versus wild type).
|
16448675 |
2006 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The addition of cetuximab to first-line chemotherapy seems to benefit patients with KRAS G13D-mutant tumors.
|
22734028 |
2012 |
Neoplasm Metastasis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Target sequencing analysis revealed, both in primary tumor and metastasis, a pathogenic KRAS gene missense mutation c.38G > A p.(Gly13Asp) and a likely pathogenic CTNNB1 gene missense mutation c.94G > A p.(Asp32Asn).
|
31823050 |
2020 |
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
|
23406027 |
2013 |
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Recruitment, particularly of patients with the rare G13D mutation, will demonstrate the ability for international collaboration to run prospective trials in small colorectal cancer molecular subgroups.
|
27246726 |
2016 |
Malignant neoplasm of colon and/or rectum
|
|
0.040 |
GeneticVariation
|
BEFREE |
Recruitment, particularly of patients with the rare G13D mutation, will demonstrate the ability for international collaboration to run prospective trials in small colorectal cancer molecular subgroups.
|
27246726 |
2016 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
GeneticVariation
|
CLINVAR |
RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.
|
22407852 |
2012 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
GeneticVariation
|
CLINVAR |
RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study.
|
2278970 |
1990 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
GeneticVariation
|
CLINVAR |
RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.
|
3122217 |
1987 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
|
20921465 |
2010 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
|
20921465 |
2010 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
|
20921462 |
2010 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
|
20921462 |
2010 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
|
16361624 |
2005 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
|
16361624 |
2005 |
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study).
|
27878354 |
2017 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Prior to treatment there were significant metabolic differences between SW48 WT and SW48-KRAS-G13D tumors, reflecting higher oxidative stress and glucose utilization in the KRAS-G13D tumors.
|
26709701 |
2015 |
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase II trial of sorafenib in metastatic thyroid cancer.
|
19255327 |
2009 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with KRAS wild-type tumors have a longer progression-free survival (7.30 months [95% CI, 4.48-10.12 months]; HR 0.46 [95% CI, 0.23-0.91]; P = .025) and overall survival (19.0 months [95% CI, 10.2-27.8 months]; HR 0.32 [95% CI, 0.15-0.69]; P = .004) than patients with p.G13D-mutated tumors.
|
22537608 |
2012 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients who had mCRC with the KRAS p.G13D mutation appeared to benefit more from cetuximab than patients who had tumors with KRAS codon 12 mutations.
|
22972628 |
2013 |
Secondary malignant neoplasm of colon and/or rectum
|
|
0.090 |
GeneticVariation
|
BEFREE |
Patients who had mCRC with the KRAS p.G13D mutation appeared to benefit more from cetuximab than patients who had tumors with KRAS codon 12 mutations.
|
22972628 |
2013 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Participating laboratories contributed information on KRAS mutation frequencies, including the G13D mutation type, as well as turnaround times for tumor block retrieval and testing.
|
24811330 |
2014 |
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our findings may shed light on the mechanism of AR in CRC, namely, that the PT harbored the same mutations as the AR and the lesions in both cases harbored the KRAS G13D mutation.
|
30896620 |
2019 |